Targeting NUPR1 for Cancer Treatment: A Risky Endeavor

Salma M A Mansour; Sahar A Ali; Shaira Nofal; Sameh H Soror

doi:10.2174/1568009620666200703152523

Targeting NUPR1 for Cancer Treatment: A Risky Endeavor

Curr Cancer Drug Targets. 2020;20(10):768-778. doi: 10.2174/1568009620666200703152523.

Authors

Salma M A Mansour¹, Sahar A Ali², Shaira Nofal³, Sameh H Soror^{1

2}

Affiliations

¹ Egyptian Patent Office, Academy of Scientific Research and Technology (ASRT), 101 Kaser Al-Ainy Street, Cairo, Egypt.
² Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Ain Helwan, Helwan Cairo 11795, Egypt.
³ Department of Pharmacology and Toxicology, Faculty of Pharmacy, Helwan University, Ain Helwan, Helwan Cairo 11795, Egypt.

PMID: 32619170
DOI: 10.2174/1568009620666200703152523

Abstract

NUPR1 is a transcription factor that has attracted great attention because of its various roles in cancer. Several studies were carried out to determine its molecular targets and mechanism of action to develop novel therapies against cancer. Here, we shed light on the role of NUPR1 in different types of cancer. NUPR1 regulates a complex network of pathways that may be affected by its silencing, which can cause varying effects. Its role in some types of cancer has been reported but remains incompletely understood, whereas its roles in other types of cancers have not been reported yet. Therefore, targeting NUPR1 for cancer treatment remains challenging and risky.

Keywords: Com-1; NUPR1; cancer inhibition; cancer progression; chemoresistance; p8; stress protein.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Basic Helix-Loop-Helix Transcription Factors / antagonists & inhibitors*
Humans
Molecular Targeted Therapy*
Neoplasm Proteins / antagonists & inhibitors*
Neoplasms / drug therapy*
Neoplasms / metabolism
Neoplasms / pathology

Substances

Antineoplastic Agents
Basic Helix-Loop-Helix Transcription Factors
NUPR1 protein, human
Neoplasm Proteins